Immunoablative therapy as a treatment for aggressive multiple sclerosis

被引：11

作者：

Atkins, H

Freedman, M

机构：

[1] Univ Ottawa, Ottawa Hosp, Multiple Sclerosis Clin, Ottawa, ON K1H 8L6, Canada

[2] Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada

来源：

NEUROLOGIC CLINICS | 2005年 / 23卷 / 01期

关键词：

D O I：

10.1016/j.ncl.2004.09.004

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis is an acquired autoimmune process producing chronic central nervous system inflammation and damage. Complete ablation of the immune system with high-dose cytotoxic therapy is able to rid the body of the autoreactive immunity and control the inflammatory process. Re-establishment of a naive immune system occurs after hematopoietic stem cell transplantation. Studies show clinical benefit and define the toxicities of this procedure. The results demonstrate that the natural history of aggressive multiple sclerosis can be changed.

引用

收藏

页码：273 / +

页数：29

相关论文

共 109 条

[1] Transfer of vitiligo after allogeneic bone marrow transplantation [J].

Alajlan, A ;

Alfadley, A ;

Pedersen, KT .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (04) :606-610

[2] Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation [J].

Arbona, C ;

Prosper, F ;

Benet, I ;

Mena, F ;

Solano, C ;

Garcia-Conde, J .

BONE MARROW TRANSPLANTATION, 1998, 22 (01) :39-45

[3] Haemopoietic stem cell transplantation in Australia, 1992-95: a report from the Australian Bone Marrow Transplant Recipient Registry [J].

Atkinson, K ;

NivisonSmith, I ;

Hawkins, T .

AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1997, 27 (04) :408-419

[4]

Becker P S, 1997, Biol Blood Marrow Transplant, V3, P45

[5] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[6] Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease [J].

Bollard, CM ;

Savoldo, B ;

Rooney, CM ;

Heslop, HE .

ACTA HAEMATOLOGICA, 2003, 110 (2-3) :139-148

[7]

Breban M, 1999, ARTHRITIS RHEUM, V42, P2275, DOI 10.1002/1529-0131(199911)42:11<2275::AID-ANR3>3.0.CO

[8]

2-6

[9]

Brown S L, 1997, Biol Blood Marrow Transplant, V3, P341

[10] MONOCYTE-MACROPHAGE DIFFERENTIATION IN EARLY MULTIPLE-SCLEROSIS LESIONS [J].

BRUCK, W ;

PORADA, P ;

POSER, S ;

RIECKMANN, P ;

HANEFELD, F ;

KRETZSCHMAR, HA ;

LASSMANN, H .

ANNALS OF NEUROLOGY, 1995, 38 (05) :788-796

← 1 2 3 4 5 6 7 8 9 10 →